scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1014987844 |
P356 | DOI | 10.1007/S00228-008-0481-Y |
P698 | PubMed publication ID | 18751690 |
P5875 | ResearchGate publication ID | 23218336 |
P50 | author | Helen McIlleron | Q48287171 |
Karen Cohen | Q55446317 | ||
Ulrika S H Simonsson | Q73506261 | ||
P2093 | author name string | Peter Smith | |
Britt Jansson | |||
Doaa Elsherbiny | |||
P2860 | cites work | Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration | Q83202534 |
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4 | Q28293310 | ||
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic | Q29616520 | ||
HIV-TB co-infection: epidemiology, diagnosis & management. | Q30350510 | ||
Chronopharmacokinetics: implications for drug treatment | Q33742389 | ||
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators | Q33975889 | ||
Body composition and nutritional parameters in HIV and AIDS patients | Q35054960 | ||
Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. | Q35620036 | ||
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals | Q35804046 | ||
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans | Q35808226 | ||
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy | Q35827891 | ||
Nevirapine in the treatment of HIV. | Q35917412 | ||
Practical guidelines to interpret plasma concentrations of antiretroviral drugs | Q35929973 | ||
Role of drug metabolism for breaking tolerance and the localization of drug hypersensitivity | Q36070790 | ||
Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection | Q37361492 | ||
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery | Q40923441 | ||
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals | Q42627921 | ||
Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor | Q43705734 | ||
An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma | Q43756284 | ||
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis | Q43824019 | ||
Stability and performance of a population pharmacokinetic model | Q43868861 | ||
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population | Q44469967 | ||
The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients | Q44787744 | ||
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors | Q44905262 | ||
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals | Q45428802 | ||
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication | Q45764043 | ||
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis | Q46838565 | ||
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis | Q46906469 | ||
Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate | Q46925759 | ||
In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents | Q48497171 | ||
Disposition and biotransformation of the antiretroviral drug nevirapine in humans. | Q54408488 | ||
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450 | Q73201582 | ||
Effect of tuberculosis therapy on nevirapine trough plasma concentrations | Q73271834 | ||
Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers | Q73508511 | ||
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays | Q77198790 | ||
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM | Q77296898 | ||
Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis | Q79402194 | ||
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin | Q79738909 | ||
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration | Q80124577 | ||
P433 | issue | 1 | |
P921 | main subject | South Africa | Q258 |
tuberculosis | Q12204 | ||
nevirapine | Q263713 | ||
pharmacokinetics | Q323936 | ||
chemotherapy | Q974135 | ||
P304 | page(s) | 71-80 | |
P577 | publication date | 2008-08-27 | |
P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
P1476 | title | Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients | |
P478 | volume | 65 |
Q33839294 | Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment |
Q36905884 | Clinical pharmacokinetics of antiretroviral drugs in older persons |
Q24609011 | Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all |
Q37509532 | Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children |
Q34212799 | Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the |
Q34149022 | Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics |
Q37666456 | Management of individuals requiring antiretroviral therapy and TB treatment |
Q38720418 | Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group |
Q36276839 | Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience |
Q34405883 | Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin |
Q24631021 | Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams |
Q38865904 | Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns |
Q24602072 | Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients |
Q40736787 | Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach |
Q35598505 | Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. |
Q38207924 | Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins |
Search more.